Skip to main content
Premium Trial:

Request an Annual Quote

Genomica Adopts Shareholders Rights Plan

NEW YORK, Oct. 5 – After announcing that it would slash 100 of 150 jobs, beleaguered bioinformatics company Genomica said that its board of directors had approved a shareholders rights plan designed to protect the company in the event of an unsolicited takeover attempt.

Under the terms of the plan, all stockholders of record as of October 24, will receive rights to purchase a new series of discounted preferred stock. The rights plan has a 20 percent trigger, meaning that the rights can only be exercised if a group or individual buys 20 percent or more of the company’s common stock or announces a tender offer for that much. 

By instituting such a plan, Genomica, which closed at $2.60 on the Nasdaq on Thursday, hopes to dissuade a potential buyer from trying to overtake the company without talking with the board of directors. 

“The adoption of the rights plan is intended as a means to guard against abusive takeover tactics and is not in response to any particular proposal,” Genomica said in a statement released Thursday after the close of trading.

On Thursday, Genomica of Boulder, Colo., announced that it was reducing its workforce by 67 percent after determining that the company could not realize its original goals of delivering novel software tools to the genomics market. 

The company now plans to focus on combining its genetic analysis software with hardware. 

Genomica's customers include AstraZeneca, GlaxoSmithKline, Aventis, and the National Cancer Institute. Genomica also has strategic alliances with Applied Biosystems and Celera.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.